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Abstract
Background: Hand eczema is the most frequently recognized occupational disease in Denmark with an incidence
of approximately 0.32 per 1000 person-years. Consequences of hand eczema include chronic severe eczema,
prolonged sick leave, unemployment, and impaired quality of life. New preventive strategies are needed to reduce
occupational hand eczema.
Methods/Design: We describe the design of a randomised clinical trial to investigate the effects of classification of
hand eczema plus individual counselling versus no intervention. The trial includes health-care workers with hand
eczema identified from a self-administered questionnaire delivered to 3181 health-care workers in three Danish
hospitals. The questionnaire identifies the prevalence of hand eczema, knowledge of skin-protection, and exposures
that can lead to hand eczema. At entry, all participants are assessed regarding: disease severity (Hand Eczema
Severity Index); self-evaluated disease severity; number of eruptions; quality of life; skin protective behaviour, and
knowledge of skin protection. The patients are centrally randomised to intervention versus no intervention 1:1
stratified for hospital, profession, and severity score. The experimental group undergoes patch and prick testing;
classification of the hand eczema; demonstration of hand washing and appliance of emollients; individual
counselling, and a skin-care programme. The control group receives no intervention. All participants are reassessed
after six months. The primary outcome is observer-blinded assessment of disease severity and the secondary
outcomes are unblinded assessments of disease severity; number of eruptions; knowledge of skin protection; skin-
protective behaviour, and quality of life.
Trial registration: The trial is registered in ClinicalTrials.Gov, NCT01012453.
Background
Hand eczema (HE) is a long-lasting disease with a point
prevalence of 9.7% in the background population [1]
and an incidence reported to be 5.5 to 8.8 per 1000 per-
son-years [2,3]. Occupational hand eczema (OHE) is the
most frequently recognized occupational disease in Den-
mark with an incidence of approximately 0.32 per 1000
person-years [4]. Other studies have revealed that the
annual incidence of new reports of occupational skin
diseases is 0.7 to 0.8 per 1,000 employees [5,3] and the
number of unreported occupational skin conditions are
many times greater. Despite governmental attempts to
reduce exposures to harmful occupational allergens, the
number of new OHE patients has remained almost
unchanged during the past decade [4]. The prevalence is
highest in females aged 20-30 years and there is an
increased risk in occupations with high exposure to wet
work, skin irritants, and contact allergens [1,2]. Compli-
cations and consequences of occupational hand eczema
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unemployment, and impaired quality of life [6-10].
In Denmark, 21% of the recognized occupational skin
diseases are represented by health-care workers [11].
Nurses, assistant nurses, and nursing aids are particularly
at high risk, about a third reporting hand eczema [12].
Among factors that can lead to OHE are wet work
with frequent hand washing, use of protective gloves,
and local disinfectants [13-15]. There are no data avail-
able on the quantitative exposure to wet work in the dif-
ferent specialties and professions in a hospital. Better
methods to assess the exposure to wet work are needed,
and information on allergens and irritants related to
development of hand eczema is lacking [16].
Clinical data
Preventive measures and skin-care programmes have
shown a significant positive effect in the prevention of
HE among health-care workers [17-20], and a recent
study on Danish health-care workers shows that preven-
tive efforts are necessary in hospitals [12]. Skin-care pro-
grammes have also been effective in studies of other
occupations such as hairdressers [21,22], gut cleaners
[23], and cheese dairy industry workers [24]. Several of
the mentioned trials were conducted as cluster rando-
mised trials [17-21,23,24] and assessed primary preven-
tion [17-20,23,24].
Secondary prevention of HE in individual geriatric nurses
was examined in Germany in 2004 [25]. The participants
were initially referred to the authorities (Berufsgenos-
senschaft fur Gesundheitsdienst und Wohlfahrtspflege,
BGW) by their local dermatologist who suspected occupa-
tional skin disease. All participants were interviewed prior
to trial initiation. The intervention was complex and com-
prised four visits in six months including one-to-one con-
sultation by a dermatologist, three educational seminars
with hands-on training in the correct use of skin protection
and dermatologic treatment by en educationalist focusing
on attitudes toward illnesses and motivation to remain at
work. At each visit Δ transepidermal water loss (Δ TEWL)
was measured. The intervention resulted in improvement
in objective dermatologic findings and skin physiologic
data (TEWL).
In Germany there is a special course of action for
health-care workers with occupational skin disease [26].
Whenever a skin disease is reported to the BGW, the
patient is immediately invited to attend a 2-day skin
protection course that is organised in cooperation with
dermatologists/allergists, specialists in occupational
medicine, hygiene specialists, and BGW staff members.
The educational part of the skin protection courses is
complemented by a medical part obtained by a derma-
tologist in each patient. This comprises medical history
including atopic dermatitis, further diagnostics, therapy,
skin protection, and an assessment of whether the
patient can remain in the job. The findings are sent to
the BGW who decide how to handle the patient in the
future. This can vary from initiation of a 3-weeks inpati-
ent treatment programme (tertiary inpatient individual
prevention programme) to initiation of an advisory/
expert’s opinion. A follow-up investigation based on tel-
ephone interviews on 206 of 253 health-care workers
showed that the skin lesions had decreased significantly,
skin care and skin protection had improved, while the
frequency of reported hand washing was reduced. A sig-
nificantly positive impact on quality of life was also
observed [27].
With respect to secondary prevention of HE, valid
randomised clinical trials are lacking. Treatments are
often used without differentiation between HE subtypes,
and only a few clinical studies have identified subtypes
[28-33]. According to morphology and aetiology, HE
can be divided in the following subtypes: allergic contact
dermatitis (ACD), irritant contact dermatitis (ICD), ato-
pic HE (AHE), vesicular HE, hyperkeratotic and discoid
HE. Combinations of the subtypes exist of which ACD
a n dI C Da r et h em o s tc o m m o nf o l l o w e db yA H Ea n d
ICD [33]. In order to establish an effective prevention
programme it is necessary to understand the aetiology
of HE. In a Danish study on patients with OHE, irritant
contact dermatitis was found to occur more frequently
than allergic contact dermatitis [34]. This was also
found in a recent German study on geriatric nurses
from nursing homes and home care facilities [35] and in
a study on 1301 health-care workers from 1995 [36]. On
the contrary, an English study on nurses with OHE
found that allergic contact dermatitis was more com-
mon [37]. Previous studies indicate that the patient’s
knowledge of the disease (HE) is important for the prog-
nosis of the disease [38,39].
The effect of a prevention programme consisting of a
combination of classification of HE and individual,
work-related counselling in skin protective behaviour,
has not yet been investigated in Denmark. The HET
trial is the first trial on secondary prevention that is
individually randomised and stratified according to hos-
pital (the three different hospitals involved), profession
(physicians compared to nurses, nursing aids, and bio-
technicians), and Hand Eczema Severity Index (HECSI)
score.
Methods and Design
Trial participants
The trial participants are identified through a self-admi-
nistered questionnaire comprising 3,181 health-care
workers in three Danish hospitals in the same geogra-
phical region of the country. The questionnaire
addresses the prevalence of HE, exposures and risk
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ments, duty hours, and professions. Furthermore, it
addresses the knowledge of skin-protective behaviour
among the health-care workers.
Inclusion criteria
- Participants who answered “yes” to the validated
question “Have you had hand eczema within the
past twelve months?”
- Informed written consent
Exclusion criteria
- Pregnancy
- Systemic use of immunosuppressive drugs
- Systemic use of retinoids
- Active psoriatic lesions on the hands
- Any serious medical condition which, in the opi-
nion of the investigator, may interfere with the eva-
luation of the results
- Lack of informed written consent
Design
HET is a randomised, observer-blinded parallel trial. All
included participants are clinically examined at the
beginning and at the six months follow-up in the trial.
Half of the participants will be randomised to the
experimental intervention, the other half to the control
intervention consisting of no intervention. The partici-
pants in the experimental group will, after the first clini-
cal examination, pass on directly to the intervention
which includes an allergological examination (patch and
prick testing). Three days later they will be examined by
a physician who will interpret the patch test and give a
thorough, individual guidance in skin protection and
occupational safety. The clinical examination of all parti-
cipants at six-months follow-up will examine the out-
comes in the intervention and the control group
(Figure 1).
Randomisation
Randomisation will be individual and performed cen-
trally at the Copenhagen Trial Unit (CTU) according to
a computer generated allocation sequence with a block
size unknown to the investigators. After a clinical exam-
ination, an investigator will contact the CTU by tele-
phone and the CTU staff will randomise the participant
to intervention or control group. The participants in the
intervention group will then pass on directly to the
intervention and they will be told not to share knowl-
edge during the investigation. The percentage of partici-
pants allocated per intervention will be 50:50.
Randomisation will be stratified according to three fac-
tors: hospital (the three hospitals involved), profession
(physicians compared to nurses, nursing aids, and
biotechnicians), and HECSI score at entry (HECSI <8
versus HECSI ≥8).
Detailed description of the experimental intervention
A self-administered questionnaire was distributed to all
nurses, physicians, nursing aids, and laboratory techni-
cians in three Danish hospitals, 3,181 individuals in all.
The questionnaire was based on a standardised question-
naire for work-related skin diseases and exposure - the
Nordic Occupational Skin Questionnaire (NOSQ-2002)
[38]. Wherever needed questions were modified to the
hospital environment. The questionnaire was distributed
electronically by email and those who did not respond
were sent a paper version.
The questionnaire investigates the prevalence of HE
among health-care workers and the risk factors/expo-
sures (amount of hand washing, use of hand disinfec-
tants, protective gloves, emollients, etc) related to
different hospital wards (medical, surgical, in- and out
patient wards), duty hours, working procedures, and
professions. The participants with HE were asked about
self-evaluated disease severity and knowledge of skin
protection was evaluated through multiple choice ques-
tions. Questions on domestic exposures as well as aller-
gic and atopic dispositions were also posed.
The questionnaire identified 398 individuals who
answered “yes” to the question: “Have you had hand
eczema within the past year?”[40]. These individuals will
be invited by a personal letter to a clinical examination
which will focus on disease severity, self-evaluated dis-
ease severity, registration of eruptions through the past
quarter, and quality of life. Disease severity will be mea-
sured by the use of the HECSI score, which is a vali-
dated scoring system including scoring of erythema,
infiltration, vesicles, fissures, scaling and oedema [41] as
well as scoring of the size of the affected area. The
HECSI score ranges from 0 (no HE) to 360 (maximum
degree of HE). Self-evaluated disease severity will be
reported by the participants by use of a validated photo-
graphic guide [42]. Number of eruptions through the
past quarter will be reported as the number given by
the participant. Quality of life will be registered by use
of Dermatology Life Quality Index (DLQI) [43,44], a
validated dermatology-specific questionnaire, which has
previously proved useful for assessment of quality of life
in patients with HE [10,45]. Skin protective behaviour
will be studied by specific questions developed from a
skin protection programme [46] and through informa-
tion withdrawn from the questionnaire about daily
handwashing, use of hand disinfectants, protective
gloves, and emollients.
The person responsible for the clinical examination is
a health-care person who has received training in the
use of HECSI-score by a dermatologist. The time bur-
den of the clinical examination is fifteen minutes.
After the clinical examination the participants are ran-
domised to the intervention or the control group. The
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directly from the clinical examination to the intervention.
They will be tested with a patch test (allergens: nickel sul-
fate, wool alcohols, neomycin sulfate, potassium dichro-
mate, caine mix, fragrance mix, colophony, paraben mix,
negative control, balsam of peru, ethylenediamine dihy-
drochloride, cobalt dichloride, p-tert-butylphenol formal-
dehyde resin, epoxy resin, carba mix, Black Rubber mix,
Cl+ Me- isothiazolinone, quaternium-15, mercaptoben-
zothiazole, p-phenylenediamine, formaldehyde, mercapto
mix, thimerosal, thiuram mix, chlorhexidine digluconate
0.5%, primin 0.01% petrolatum, sesquiterpene lactone
mix 0.1% petrolatum (pet), budesonide 0.01% pet, tixocor-
tol pivalate 0.1% pet, hydroxyisohexyl-3-cyclohexene car-
boxaldehyde 5% pet, methyldibromo glutaronitrile 0.5%
pet, fragrance mix II 14% pet) and a prick test (Alk-Abello
soluprick standard series, chlorhexidine 0.5%, latex) for
relevant allergies that could explain the presence of HE.
Patch and prick tests will be performed by a nurse. The
time burden is fifteen minutes for the patch and prick
testing.
Three days after application of the patch tests, a phy-
sician will interpret the patch test and subtype the HE
diagnosis. The participants will demonstrate how they
apply an emollient on their hands by use of a fluores-
cent lotion and UV-light (GlitterBug Potion) to detect
areas where the lotion is not properly applied. There-
after the emollient is washed off, and the investigator
will register how the handwashing is performed by the
participant. Correct instructions in handwashing/appli-
ance of emollients will be given thereafter as well as
individual, thorough counselling in occupational safety
and skin protection based on a skin care programme
[46] and individual information on protective behaviour.
The time burden will be 20-30 minutes.
Any participant who presents in the trial with severe
HE that needs medical treatment will be prescribed with
moisturizers or local corticosteroids depending on sever-
ity. For further therapy, if needed, the participants will
be referred to their general practitioner.
Detailed description of the control intervention
The participant in the control group will undergo the
questionnaire assessment as well as the initial clinical
examination including HESCI score assessment.
Any participant who present in the trial with severe
HE that needs medical treatment will be prescribed with
moisturizers or local corticosteroids depending on sever-
ity. For further therapy, if needed, the participants will
be referred to their general practitioner.
After the six-month follow-up individual counselling
and patch and prick test will be offered to the control
participants.
Concomitant medications
Medication not permitted during the trial
Systemic immunosuppressive drugs (such as
azathioprine, cyclosporine, or prednisolone).
Systemic retinoids.
Medication permitted during the trial
Local immunomodulators (such as corticosteroids,
pimecrolimus, or tacrolimus).
All other medication that does not affect the
immune system including rescue medication.
Monitoring for participant compliance
Participant compliance will not be monitored during the
intervention period.
Follow-up at six months
All participants from the intervention group and the
control group will have a clinical examination with
registration of disease severity, self-evaluated disease
severity, registration of eruptions through the past three
months and quality of life by using the same instru-
ments as mentioned at entry into the trial. Both groups
will have a new questionnaire including multiple choice
questions about knowledge of skin protection and ques-
tions on skin protective behaviour. The questions will
be identical to those asked at entry to the trial.
After the clinical follow-up examination, the partici-
pants from the control group will be offered allergologi-
cal patch test (European Standard Series; TRUE Test
P a n e l1a n d2a n dc h l o r h e x i d i n e )a n dp r i c kt e s t( s t a n -
dard test, chlorhexidine and latex) applied by a nurse.
Three days after appliance a physician will interpret
patch test results, classify HE and give advise regarding
relevant allergies, skin protection, and occupational
safety.
Blinding
The trial is observer blinded and involves three investi-
gators. Investigator 1 (the outcome assessor) is responsi-
ble for the clinical examination at entry and follow-up
and will, together with the statistician, be the only
blinded persons in the trial. The randomisation and allo-
cation will not be done until after the first clinical
examination, and the participants will be told not to
share information with investigator 1 at follow-up.
Investigator 2 (a nurse) will be responsible for patch and
prick tests at entry and follow-up. Investigator 3 (a phy-
sician) will be responsible for subtyping the HE, inter-
preting the patch test at entry and follow-up and
counselling of the intervention group at entry, and the
control group at follow-up. Investigator 3 will be admin-
istrating the interventions and assessing the secondary
outcomes.
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ing knowledge among the participants. To minimise this
problem, the participants will be told not to share
knowledge with colleagues during the trial.
Intervention accountability
All necessary materials and tools will be handled as
prescribed.
Trial conduct
The trial will be conducted in compliance with the pro-
tocol approved by the Danish Data Protection Agency
and the local ethics committee. No deviation from the
protocol will be implemented without prior review and
approval of these authorities.
Trial objectives
The HET trial is based on the complex intervention of
precise classification of HE, allergological investigation,
and individual counselling compared with a control
group receiving no intervention.
Efficacy variables
The effects that are to be assessed in the trial are the
following:
Primary outcome
Objective blinded assessment of disease severity (HE),
measured as the difference in HECSI-score at follow-up
minus the HECSI-score at time entry.
Secondary outcomes
Subjective assessment of disease severity (HE), measured
by use of a photographic guide, at follow-up minus at
entry.
Number of eruptions registered by the participant
through the past three months of the trial at follow-up
minus at entry.
Knowledge of skin protection measured as numbers of
points achieved in a repeated multiple choice question-
naire on skin protection at follow-up minus at entry.
Skin protective behaviour measured as number of
daily handwashing and use of hand disinfectants and
emollients at follow-up minus at entry. Skin protective
behaviour will also be measured as number of correct
answers according to questions developed from a speci-
fic skin care programme at follow-up minus at entry.
Quality of life will be measured as number of points
scored in the Dermatology Life Quality Index at follow-
up minus at entry.
Adverse events
Any undesirable event occurring to a participant during
a clinical trial, whether or not related to the trial, is con-
sidered to be an adverse event.
Since no drugs are used in the trial, the only expected
adverse events are unexpected reactions to patch and
prick tests. These can be allergic and eczematous reac-
tions with redness of the skin, vesicles, itching, and urti-
caria. However, these symptoms can be present as a
normal, positive response to patch and prick testing. If
the reactions are severe and long lasting with involve-
ment of skin areas other than the tested areas, it will be
considered as an adverse event.
Systemic reactions are rare and can be astma, pruritic
eyes, nose or pharynx, generalised pruritus, sneezing, and
generalised urticaria [47]. Anaphylactic reaction is extre-
mely rare [48] and will be reported as a serious adverse
event. Adverse and serious adverse events will be reported
in compliance to the ethics committee requirements.
Serious adverse events
Any serious adverse event will be registered. These
include any experience that suggests a medically signifi-
cant hazard including any event that: results in death; is
life threatening; requires inpatient hospitalisation; results
in persistent or significant disability/incapacity; is a con-
genital anomaly/birth defect.
Recording of adverse events
At six months, all adverse events either observed by the
investigator or reported by the participant will be
recorded in the participants file by the investigator and
evaluated. Following variables will be recorded: descrip-
tion of event, onset and end of event, severity, relation
to intervention product, action taken and outcome.
Type and duration of the follow up of participants after
adverse events
Any adverse event occurring during the trial will be
treated according to established standards and the parti-
cipant will be followed until the event has disappeared
or until the condition has been stabilised.
Ethical considerations
The intentions with the experimental intervention are to
improve behaviour and knowledge of skin protection
among health-care workers in order to prevent HE in
this population. No drugs will be used in the trial and
the participants are not put on any unacceptable level of
risk and there are no perceived harms connected to the
trial other than disadvantages correlating to patch and
prick testing described above. Patch and prick testing
are established diagnostic procedures that are used in
daily practise in dermatological clinics and departments.
All participants are offered a standard allergological
investigation to detect relevant allergies that can have an
impact on HE. However, participants in the intervention
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and participants in the control group will be tested after
follow-up. Thus the participants in the control group are
allergologically diagnosed six months later than the inter-
vention group, and this is considered to be the main ethi-
cal dilemma in the trial. During the intervention period
the participants in the control group do not know if they
are allergic, and therefore might not avoid the relevant
allergens. This can have a negative impact on the eczema,
b u ti tw i l ln o td i f f e rf r o mt h ec o n d i t i o n sb e f o r eo n s e to f
the trial. We do, however, consider that the collective
advantages exceed the disadvantages for the population
as a whole. By the end of the trial all participants have
been treated equally. In Denmark there are at present no
standard procedures or standard treatments when it
comes to patients with HE, and the participants in the
control group are not considered to be treated worse
than ‘usual standard care’. HE patients are followed by
general practitioners, dermatologists in private practise,
or dermatological departments. In general practise, aller-
gological investigations are not done. In dermatological
practise or departments allergological testing is usually
done depending on the patient’s history, the severity of
the eczema, and treatment response. The treatment
usually includes avoidance of wet work and irritants, use
of emollients, and prescription of topical corticosteroids.
Other treatments that can be used for HE include topical
calcineurin inhibitors, oral steroids, azathioprine or
cyclosporine, ultraviolet (UV) radiation, psoralene and
UV-A radiation, alitretinoin, and retinoids.
Participant information and informed consent
This HET protocol has been approved by the local
Ethics Committee. All participants considered for this
trial will be provided with written and oral information
on the trial so that the participants can make an
informed decision about their participation in this trial.
The consent form will be signed by the participant and
the investigator seeking the consent.
Data collection
Data will be registered directly in standardised paper
record forms at each visit by investigator 1, 2 and 3. All
data from the paper files will be registered electronically
in SPSS. This will be done manually by double data
entry performed by the investigators:
At entry to the trial, all participants will have three
coded case record forms to be used by investigator 1, 2
and 3. At follow-up, three new coded case records will be
used.
Participant withdrawal
The participants are free to withdraw his/her informed
consent from the trial at any time without effecting
future treatment. All participants who enter the trial
will be accounted for in the report, whether or not they
are included in the analysis. All reasons for exclusion
from analysis will be documented. Participants who do
not attend the follow-up visit will be identified and a
letter will be sent containing a questionnaire on reasons
for drop out and its relationship to treatment and out-
come, on number of eruptions, subjective severity
assessment, quality of life, knowledge of skinprotection,
and skin protective behaviour. The questions will be
identical to the questions asked at the clinical examina-
tion supplemented by questions on skin protective beha-
viour for the participants in the intervention group. If
the participant does not respond to the letter, they will
be contacted by telephone and asked to take part in a
telephone interview by investigator 1. The telephone
interview will include the same questions as in the let-
ter. Information on objective severity assessment cannot
be obtained since that demands a clinical examination.
Subjective severity assessment can only be obtained by
the use of the photographic guide that will be distribu-
ted in a letter.
Sample size estimation
The clinical trial is planned to include a minimum of
262 participants. The sample size calculation is based on
t h em e a nH E C S Is c o r e( p r i m a r yo u t c o m e )a f t e rs i x
months, which is expected to be 10 in the intervention
group and 14 in the control group. Alpha error level is
5% and beta error level is 20%. With the standard devia-
tion of 13 on the HESCI score, the sample size calcula-
tion is 131 each intervention group. http://www.
dssresearch.com/toolkit/sscalc/size_a2.asp.
Since the prevalence of HE is approximately 10% in
the health-care worker population, 3181 health-care
workers were invited to participate in the questionnaire
survey. This was the number of employed health-care
workers (doctors, nurses, nursing aids and biotechni-
cians) in the three included hospitals. The results of the
survey identified 398 health-care workers with HE dur-
ing the past year. All 398 health-care workers are invited
to join the trial. We do, however, not expect that all
invited HCW will participate. The time span between
the survey and the clinical trial is five months and there
will be a natural drop out among the invited health-care
workers.
Statistical methods and significance
Statistical analysis will be performed in SPSS. Compari-
sons of quantitative exposures between different working
conditions will be analysed using the Mann-Whitney test.
Non-parametric statistics (Mann-Whitney test) will be
used to compare independent groups. Changes between
matched data over time (6 months) will be analysed
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of marginal homogeneity will be used for ordinal data.
The significance level will be a p value ≤ 0.05.
The number of participants included in the statistical
analyses will be reported. We intend to conduct inten-
tion-to-treat analyses.
A trained statistician will guide in the statistical
aspects of the trial, and all data analyses will be con-
ducted with the statistician blinded for intervention
groups.
Accountability procedure for missing data/population for
analysis
An analysis of dropouts will be made to describe the
demographic data of the population. The analysis will
be used to compare the drop outs with the participants
and investigate whether the two groups differ in demo-
graphic conditions. If more than 5% of the data is miss-
ing, multiple imputation will be performed if data are
not missing completely at random.
Direct access to source data and documentation
The trial is not planned to be monitored by any other
authority than the investigators. If a relevant authority,
as the Danish Research Ethics Committee System or the
Danish Data Protection Agency, plan to inspect the trial,
all data and files will be available for inspection in
accordance with the GCP guidelines.
Data handling and record keeping
Data will be handled and recorded in case record
forms and kept in records marked with investigator
number, patient identification number, name of hospi-
tal, and time. After follow-up all the case report forms
from each participant will be collected in individual
files. Any change in the files or case report forms will
be documented with date and signature of the
investigator.
Data from the records will be registered electronically
in SPSS for statistical analyses. This will be done manu-
ally. Records will be archived for at least five years after
termination of the trial.
Quality control and quality assurance
To ensure that the trial is conducted and reported in
compliance with this protocol, the data will be moni-
tored internally and externally. The investigators will
monitor the data and check for systematic errors. All
data will be registered in paper record forms and kept
at an investigator file site only available for the investi-
gators. The data will be registered electronically by the
investigators using double data entry. A random 5% of
the data will be monitored by the investigators. Data
will be handled with confidentiality.
Trial organisation
The trial takes place in three hospitals in Region Zeal-
and who has provided the participants and localities for
investigation. The Danish Working Environment
Authority has been involved in the creation of the
questionnaire.
The investigators are responsible for the protocol,
conducting of the trial, and all other aspects involved.
Finance and insurance
The trial is financed by the Danish Working Environ-
ment Authority and Region Zealand Health Scientific
Research Foundation who cover all expenses related to
the trial. The participants in the study are covered by
their work insurance and the patient insurance (Patient-
forsikringen: http://www.patientforsikringen.dk)
Discussion
The overall purpose of the HET trial is to develop new
strategies for secondary prevention of HE in health-care
workers. The trial focuses on HE among nurses and
nursing aids who account for almost 25% of recognized
OHE in Denmark.
The project will assess exposures that can lead to
OHE in hospitals and relate them to different wards,
duty hours, and professions. It also focuses on the
knowledge of skin protection and skin protective beha-
v i o u ri nh e a l t h - c a r ew o r k e r s ,w h i c hm a ym a k ei tp o s s i -
ble to improve preventive strategies.
The project will also investigate the aetiology of HE in
health-care workers. Aetiology and assessment of expo-
sures in health-care workers are important factors for
f o c u s e dp r e v e n t i o no fH Ei nt h ef u t u r e .T h i sc o m b i n e d
with individual, focused counselling could make a basis
for a new strategy in prevention of HE in health-care
workers.
We have designed the HET trial in order to reduce
the risks of systematic errors (’bias’), random errors
(’play of chance’), and design errors to a minimum
[49-51]. The risks of bias have been sought reduced by
conducting central randomisation stratified for impor-
tant prognostic factors. Furthermore, we employ blinded
assessment of the primary outcome measure and will
analyse our data with ‘intention to treat’. We are aware
of the fact that the secondary outcome measures are at
risk of being assessed with some bias favouring the
experimental intervention. The risk of random error has
been reduced by basing our sample size estimation on
conservative estimate regarding the minimal relevant
difference between the control and experimental group.
Randomised trials on complex interventions need
proper description of the interventions, both before the
launch of the trial as well as after the conduct of the
trial [52]. In the present article we describe how we
Ibler et al. BMC Dermatology 2010, 10:8
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Page 8 of 10intend to apply the interventions in the experimental
group and the control group. We will at the six month
follow up collect information on how the interventions
have been administered in the two intervention groups,
making it possible for us to ascribe any significant dif-
ferences regarding the primary outcome to the interven-
tions provided. Any significant differences regarding the
secondary outcomes ought to be interpreted conserva-
tively, first because they will be assessed without blind-
ing and second because they may be due to random
errors.
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